Aptose Biosciences Inc.
APS.TO
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 11.15M | 11.52M | 12.68M | 13.62M | 15.59M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 26.26M | 36.20M | 40.91M | 48.02M | 52.36M |
| Operating Income | -26.26M | -36.20M | -40.91M | -48.02M | -52.36M |
| Income Before Tax | -25.43M | -35.80M | -40.29M | -47.17M | -51.21M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -25.43 | -35.80 | -40.29 | -47.17 | -51.21 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -25.43M | -35.80M | -40.29M | -47.17M | -51.21M |
| EBIT | -26.26M | -36.20M | -40.91M | -48.02M | -52.36M |
| EBITDA | -26.23M | -36.15M | -40.85M | -47.94M | -52.27M |
| EPS Basic | -47.58 | -91.96 | -133.59 | -188.60 | -233.07 |
| Normalized Basic EPS | -29.74 | -57.47 | -83.50 | -117.88 | -145.67 |
| EPS Diluted | -47.58 | -91.96 | -133.59 | -188.60 | -233.07 |
| Normalized Diluted EPS | -29.74 | -57.47 | -83.50 | -117.88 | -145.67 |
| Average Basic Shares Outstanding | 2.80M | 1.88M | 1.47M | 1.12M | 891.50K |
| Average Diluted Shares Outstanding | 2.80M | 1.88M | 1.47M | 1.12M | 891.50K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |